Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Dosing and efficacy endpoint of the trial have been informed by earlier studies, including a failed Phase III.
You may also be interested in...
Merck, Addex Parkinson’s Venture To Develop Treatments That Target Glutamate Receptor
Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.
Merck, Addex Parkinson’s Venture To Develop Treatments That Target Glutamate Receptor
Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.
Merck Serono Phase III Trial Extension For Safinamide In Parkinson’s Misses Endpoint
Merck will pursue lower dose in future clinical trials, firm tells “The Pink Sheet” DAILY.